Hologic climbs on mammography study results
Shares of Hologic Inc. rose Wednesday after the company said a study shows that using 3-D mammogram devices along with 2-D scans improves the rate of breast cancer detection and reduces false positives.
The study was published in Radiology, the journal of the Radiological Society of North America. The study concludes that radiologists were better able to identify cancers when they were able to use both two-dimensional and three-dimensional scans of the breast. Hologic said the rates of cancer detection increased 27 percent and detection of invasive cancer increased 40 percent.
The study was based on more than 12,000 scans taken at a Norwegian hospital.
Hologic shares rose $1.47, or 7 percent, to $22.36 on Wednesday. Earlier the shares peaked at $23.22, their highest price since May 2011.
The Bedford, Mass., company's Selenia Dimensions system generates both two-dimensional and three-dimensional images of the breast, and it captures images from multiple angles. It is the first 3-D mammography device and is intended to generate more accurate diagnoses so healthy women don't need additional scans. The system has been used in Europe since 2008 and was approved in the U.S. in 2011.